National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Liposomal irinotecan (Onivyde®) is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.

Rapid Review

Commenced Completed Outcome
13/06/2017 13/07/2017 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.

NCPE Assessment Process Complete
Rapid review Re-commissioned 15/06/2020
Rapid review completed 14/07/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pegylated liposomal irinotecan compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 14/07/2020
Pre-submission consultation with Applicant Scheduled
Current status Pre-submission consultation scheduled